Drug Profile

CR 001 - Crescent Biopharma

Alternative Names: CR-001 - Crescent Biopharma

Latest Information Update: 20 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Crescent Biopharma; Paragon Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Programmed cell death 1 receptor antagonists; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 Jun 2025 Crescent Biopharma plans to initiate a phase I trial for Solid tumours (Parenteral)
28 Apr 2025 Crescent Biopharma announces intention to submit IND to Regulatory authority for Solid tumours (Parenteral) in the fourth quarter of 2025
29 Oct 2024 Preclinical trials in Solid tumours in USA (Parenteral), prior to October 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com